Johnson & Johnson Remains Too Big to Succeed

NEW YORK (TheStreet) -- Few stock sectors are as reliable as drugs and health care, and astute investors know that companies such as Merck (MRK), Pfizer (PFE) and Abbott Laboratories (ABT) have delivered healthy returns over the years.

One stock that investors have become less enamored with, however, is Johnson & Johnson ( JNJ).

Johnson and Johnson

The company has made recent mistakes, including product recalls, and its stock performance has been uninspiring for the most part.

Johnson & Johnson's first quarter was not so healthy, even though its numbers beat analysts' estimates.

Revenue was $16.1 billion, down slightly from the same quarter a year before.

Earnings were $3.8 billion, or $1.37 a share, up 1.5% from a year before.

But the headline numbers obscured some disappointing details.

Revenue from the U.S. declined by 5.1%.

The only unit that showed growth was business pharmaceutical sales, while consumer sales and medical devices declined by 2.4% and 0.3%, respectively.

Also disappointing was that management offered full-year EPS guidance of a conservative $5.07 to $5.17.

This failed to dispel concerns about litigation costs related to Johnson & Johnson's DePuy medical device unit.

Johnson & Johnson seems to have taken a "we know best" attitude when it comes to Wall Street's wish that it break itself into smaller and -- it is hoped -- more valuable parts.

Management's insistence on keeping the company one large conglomerate could make it lose loyal investors.

In fact, this insistence is remarkable when rivals Pfizer and Abbott Laboratories have enjoyed positive results from opting to separate their businesses.

Although I'd like to give Johnson & Johnson the benefit of the doubt on this issue because it's been in business so long, the company has yet to prove that it can make a solid turnaround as long as it stays "too big to succeed." Bottom Line

As dominant as Johnson & Johnson has been over the past several decades, it has stumbled repeatedly over the past five years.

Although Johnson & Johnson's shares are slightly less expensive than Pfizer's ( PFE), its growth doesn't support its having a higher price-to-earnings multiple than Novartis ( NVS) or Covidien ( COV).

For 2012, analysts are expecting 2.2% sales growth on EPS of $5.13, which is the middle of Johnson & Johnson's guidance.

Even if the company's results are at the top of its range, one has to wonder whether it will be enough to compel investors to buy the stock.

At the time of publication, the author held no positions in any of the stocks mentioned.

More from Opinion

These 5 Tech Giants Still Aren't That Expensive

These 5 Tech Giants Still Aren't That Expensive

50 Stocks That Could Be Shredded If a U.S. Trade War With China Ignites

50 Stocks That Could Be Shredded If a U.S. Trade War With China Ignites

Intel CEO Brian Krzanich's Ouster Proves CEOs Aren't Above the Rules

Intel CEO Brian Krzanich's Ouster Proves CEOs Aren't Above the Rules

Red Hat CFO Tells TheStreet: Tech Trends Are Still in Our Favor

Red Hat CFO Tells TheStreet: Tech Trends Are Still in Our Favor

Throwback Thursday: Intel Edition

Throwback Thursday: Intel Edition